中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 8
Aug.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(8): 1708-1714

Mechanism of action of cholangiocyte senescence in cholestatic liver disease and retated targeted therapies

DOI: 10.12449/JCH250836
  • 1a.

    Medical College Henan University of Chinese Medicine

  • 1b.

    College of Traditional Chinese Medicine Henan University of Chinese Medicine，Zhengzhou 450046，China

  • 2.

    Department of Pathology，The Third Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450008，China

Research funding:

National Natural Science Foundation of China General Project (82074340);

Key Program of Traditional Chinese Medicine Scientific Research in Henan Province (2024ZY1030)

More Information
  • Corresponding author: LIU Yanxin， liuyanxin@126.com （ORCID： 0009-0009-2649-9659）
  • Received Date: 2024-12-19
  • Accepted Date: 2024-12-31
  • Published Date: 2025-08-25
    Abstract
  • Cholestatic liver disease （CLD） is a liver condition caused by disorders in bile acid secretion and metabolism due to various reasons， and it has the common pathological features of various chronic liver diseases. In recent years， the role of cholangiocyte senescence （CS） in the pathogenesis of CLD has attracted more and more attention， and CS not only participates in the development and progression of CLD， but it is also significantly associated with the course and prognosis of the disease. Targeted clearance of senescent cholangiocytes or blocking senescence-related pathways can improve CLD. This article summarizes the role of CS in CLD， related influencing factors， and the research advances in CLD， in order to provide a theoretical reference for subsequent studies on CLD.

     

    • FullText(HTML)
  • loading
    • References(62)
  • [1]
    TRIVEDI PJ, HIRSCHFIELD GM, ADAMS DH, et al. Immunopathogenesis of primary biliary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis: Themes and concepts[J]. Gastroenterology, 2024, 166( 6): 995- 1019. DOI: 10.1053/j.gastro.2024.01.049.
    [2]
    PARK JW, KIM JH, KIM SE, et al. Primary biliary cholangitis and primary sclerosing cholangitis: Current knowledge of pathogenesis and therapeutics[J]. Biomedicines, 2022, 10( 6): 1288. DOI: 10.3390/biomedicines10061288.
    [3]
    TANAKA A. New therapies on the horizon for primary biliary cholangitis[J]. Drugs, 2024, 84( 1): 1- 15. DOI: 10.1007/s40265-023-01979-1.
    [4]
    LEVY C, MANNS M, HIRSCHFIELD G. New treatment paradigms in primary biliary cholangitis[J]. Clin Gastroenterol Hepatol, 2023, 21( 8): 2076- 2087. DOI: 10.1016/j.cgh.2023.02.005.
    [5]
    FIORUCCI S, URBANI G, DI GIORGIO C, et al. Bile acids-based therapies for primary sclerosing cholangitis: Current landscape and future developments[J]. Cells, 2024, 13( 19): 1650. DOI: 10.3390/cells13191650.
    [6]
    LUO X, LU LG. Progress in the management of patients with cholestatic liver disease: Where are we and where are we going?[J]. J Clin Transl Hepatol, 2024, 12( 6): 581- 588. DOI: 10.14218/JCTH.2023.00519.
    [7]
    CAI XR, TACKE F, GUILLOT A, et al. Cholangiokines: Undervalued modulators in the hepatic microenvironment[J]. Front Immunol, 2023, 14: 1192840. DOI: 10.3389/fimmu.2023.1192840.
    [8]
    CHUNG BK, KARLSEN TH, FOLSERAAS T. Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864( 4 Pt B): 1390- 1400. DOI: 10.1016/j.bbadis.2017.08.020.
    [9]
    TRUSSONI CE, O’HARA SP, LARUSSO NF. Cellular senescence in the cholangiopathies: A driver of immunopathology and a novel therapeutic target[J]. Semin Immunopathol, 2022, 44( 4): 527- 544. DOI: 10.1007/s00281-022-00909-9.
    [10]
    JALAN-SAKRIKAR N, GUICCIARDI ME, O’HARA SP, et al. Central role for cholangiocyte pathobiology in cholestatic liver diseases[J]. Hepatology, 2024: 10.1097/HEP. 0000000000001093. DOI: 10.1097/HEP.0000000000001093.
    [11]
    WEI WQ, JI SP. Cellular senescence: Molecular mechanisms and pathogenicity[J]. J Cell Physiol, 2018, 233( 12): 9121- 9135. DOI: 10.1002/jcp.26956.
    [12]
    OGRODNIK M, ACOSTA JC, ADAMS PD, et al. Guidelines for minimal information on cellular senescence experimentation in vivo[J]. Cell, 2024, 187( 16): 4150- 4175. DOI: 10.1016/j.cell.2024.05.059.
    [13]
    ZHANG YM, HUANG SY, XIE B, et al. Aging, cellular senescence, and glaucoma[J]. Aging Dis, 2024, 15( 2): 546- 564. DOI: 10.14336/AD.2023.0630-1.
    [14]
    CAZZAGON N, SARCOGNATO S, FLOREANI A, et al. Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis[J]. JHEP Rep, 2021, 3( 3): 100286. DOI: 10.1016/j.jhepr.2021.100286.
    [15]
    BARRON-MILLAR B, OGLE L, MELLS G, et al. The serum proteome and ursodeoxycholic acid response in primary biliary cholangitis[J]. Hepatology, 2021, 74( 6): 3269- 3283. DOI: 10.1002/hep.32011.
    [16]
    SASAKI M, SATO Y, NAKANUMA Y. Increased p16INK4a-expressing senescent bile ductular cells are associated with inadequate response to ursodeoxycholic acid in primary biliary cholangitis[J]. J Autoimmun, 2020, 107: 102377. DOI: 10.1016/j.jaut.2019.102377.
    [17]
    KYRITSI K, KENNEDY L, MEADOWS V, et al. Mast cells induce ductular reaction mimicking liver injury in mice through mast cell-derived transforming growth factor beta 1 signaling[J]. Hepatology, 2021, 73( 6): 2397- 2410. DOI: 10.1002/hep.31497.
    [18]
    WAN Y, ZHOU TH, SLEVIN E, et al. Liver-specific deletion of microRNA-34a alleviates ductular reaction and liver fibrosis during experimental cholestasis[J]. FASEB J, 2023, 37( 2): e22731. DOI: 10.1096/fj.202201453R.
    [19]
    KOSAR K, CORNUET P, SINGH S, et al. WNT7B regulates cholangiocyte proliferation and function during murine cholestasis[J]. Hepatol Commun, 2021, 5( 12): 2019- 2034. DOI: 10.1002/hep4.1784.
    [20]
    RONCA V, MANCUSO C, MILANI C, et al. Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis[J]. J Leukoc Biol, 2020, 108( 2): 659- 671. DOI: 10.1002/JLB.5MR0320-200R.
    [21]
    LAN T, QIAN SJ, TANG CW, et al. Role of immune cells in biliary repair[J]. Front Immunol, 2022, 13: 866040. DOI: 10.3389/fimmu.2022.866040.
    [22]
    SASAKI M, MIYAKOSHI M, SATO Y, et al. Modulation of the microenvironment by senescent biliary epithelial cells may be involved in the pathogenesis of primary biliary cirrhosis[J]. J Hepatol, 2010, 53( 2): 318- 325. DOI: 10.1016/j.jhep.2010.03.008.
    [23]
    ZHANG L, PITCHER LE, PRAHALAD V, et al. Targeting cellular senescence with senotherapeutics: Senolytics and senomorphics[J]. FEBS J, 2023, 290( 5): 1362- 1383. DOI: 10.1111/febs.16350.
    [24]
    WU N, MENG FY, INVERNIZZI P, et al. The secretin/secretin receptor axis modulates liver fibrosis through changes in transforming growth factor-β1 biliary secretion in mice[J]. Hepatology, 2016, 64( 3): 865- 879. DOI: 10.1002/hep.28622.
    [25]
    FERREIRA-GONZALEZ S, LU WY, RAVEN A, et al. Paracrine cellular senescence exacerbates biliary injury and impairs regeneration[J]. Nat Commun, 2018, 9( 1): 1020. DOI: 10.1038/s41467-018-03299-5.
    [26]
    KIOURTIS C, TERRADAS-TERRADAS M, GEE LM, et al. Hepatocellular senescence induces multi-organ senescence and dysfunction via TGFβ[J]. Nat Cell Biol, 2024, 26( 12): 2075- 2083. DOI: 10.1038/s41556-024-01543-3.
    [27]
    YANG Y, WANG JL, WAN JH, et al. PTEN deficiency induces an extrahepatic cholangitis-cholangiocarcinoma continuum via aurora kinase A in mice[J]. J Hepatol, 2024, 81( 1): 120- 134. DOI: 10.1016/j.jhep.2024.02.018.
    [28]
    SHANG DS, SUN DL, SHI CY, et al. Activation of epidermal growth factor receptor signaling mediates cellular senescence induced by certain pro-inflammatory cytokines[J]. Aging Cell, 2020, 19( 5): e13145. DOI: 10.1111/acel.13145.
    [29]
    LU XY, LIU L. Genome stability from the perspective of telomere length[J]. Trends Genet, 2024, 40( 2): 175- 186. DOI: 10.1016/j.tig.2023.10.013.
    [30]
    SHIM HS, IACONELLI J, SHANG XY, et al. TERT activation targets DNA methylation and multiple aging hallmarks[J]. Cell, 2024, 187( 15): 4030- 4042. e 13. DOI: 10.1016/j.cell.2024.05.048.
    [31]
    JALAN-SAKRIKAR N, ANWAR A, YAQOOB U, et al. Telomere dysfunction promotes cholangiocyte senescence and biliary fibrosis in primary sclerosing cholangitis[J]. JCI Insight, 2023, 8( 20): e170320. DOI: 10.1172/jci.insight.170320.
    [32]
    YANG L, ZHENG SJ, YANG N, et al. Research progress of inflammatory response and oxidative stress mechanism of cholestatic liver disease and intervention progress of Chinese medicine[J/OL]. China J Chin Med, 1- 10[ 2024-12-29]. http://kns.cnki.net/kcms/detail/41.1411.R.20240929.1140.006.html. http: //kns.cnki.net/kcms/detail/41.1411.R.20240929.1140.006.html

    杨柳, 郑思嘉, 杨念, 等. 胆汁淤积肝病的炎症反应和氧化应激机制及中医药干预研究[J/OL]. 中医学报, 1- 10[ 2024-12-29]. http://kns.cnki.net/kcms/detail/41.1411.R.20240929.1140.006.html. http: //kns.cnki.net/kcms/detail/41.1411.R.20240929.1140.006.html
    [33]
    von ZGLINICKI T. Oxidative stress and cell senescence as drivers of ageing: Chicken and egg[J]. Ageing Res Rev, 2024, 102: 102558. DOI: 10.1016/j.arr.2024.102558.
    [34]
    FLOREANI A, GABBIA D, de MARTIN S. Primary biliary cholangitis: Primary autoimmune disease or primary secretory defect[J]. Expert Rev Gastroenterol Hepatol, 2023, 17( 9): 863- 870. DOI: 10.1080/17474124.2023.2242771.
    [35]
    PRIETO J, BANALES JM, MEDINA JF. Primary biliary cholangitis: Pathogenic mechanisms[J]. Curr Opin Gastroenterol, 2021, 37( 2): 91- 98. DOI: 10.1097/MOG.0000000000000703.
    [36]
    SASAKI M, SATO Y, NAKANUMA Y. An impaired biliary bicarbonate umbrella may be involved in dysregulated autophagy in primary biliary cholangitis[J]. Lab Invest, 2018, 98( 6): 745- 754. DOI: 10.1038/s41374-018-0045-4.
    [37]
    LI Q, LIN Y, LIANG GY, et al. Autophagy and senescence: The molecular mechanisms and implications in liver diseases[J]. Int J Mol Sci, 2023, 24( 23): 16880. DOI: 10.3390/ijms242316880.
    [38]
    SASAKI M, MIYAKOSHI M, SATO Y, et al. Autophagy may precede cellular senescence of bile ductular cells in ductular reaction in primary biliary cirrhosis[J]. Dig Dis Sci, 2012, 57( 3): 660- 666. DOI: 10.1007/s10620-011-1929-y.
    [39]
    SASAKI M, NAKANUMA Y. Bile acids and deregulated cholangiocyte autophagy in primary biliary cholangitis[J]. Dig Dis, 2017, 35( 3): 210- 216. DOI: 10.1159/000450913.
    [40]
    ALSURAIH M, O’HARA SP, WOODRUM JE, et al. Genetic or pharmacological reduction of cholangiocyte senescence improves inflammation and fibrosis in the Mdr2-/- mouse[J]. JHEP Rep, 2021, 3( 3): 100250. DOI: 10.1016/j.jhepr.2021.100250.
    [41]
    MAHONEY SA, VENKATASUBRAMANIAN R, DARRAH MA, et al. Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence[J]. Aging Cell, 2024, 23( 3): e14060. DOI: 10.1111/acel.14060.
    [42]
    KYRITSI K, FRANCIS H, ZHOU TH, et al. Downregulation of p16 decreases biliary damage and liver fibrosis in the Mdr2－/－ mouse model of primary sclerosing cholangitis[J]. Gene Expr, 2020, 20( 2): 89- 103. DOI: 10.3727/105221620X15889714507961.
    [43]
    JONES H, HARGROVE L, KENNEDY L, et al. Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice[J]. Hepatology, 2016, 64( 4): 1202- 1216. DOI: 10.1002/hep.28704.
    [44]
    WANG Y, QIU H, CHEN SP, et al. microRNA-7 deficiency ameliorates d-galactose-induced aging in mice by regulating senescence of Kupffer cells[J]. Aging Cell, 2024, 23( 6): e14145. DOI: 10.1111/acel.14145.
    [45]
    JIA RJ, YANG F, YAN PF, et al. Paricalcitol inhibits oxidative stress-induced cell senescence of the bile duct epithelium dependent on modulating Sirt1 pathway in cholestatic mice[J]. Free Radic Biol Med, 2021, 169: 158- 168. DOI: 10.1016/j.freeradbiomed.2021.04.019.
    [46]
    KIM JY, KIM SH, SEOK J, et al. Increased PRL-1 in BM-derived MSCs triggers anaerobic metabolism via mitochondria in a cholestatic rat model[J]. Mol Ther Nucleic Acids, 2023, 31: 512- 524. DOI: 10.1016/j.omtn.2023.01.017.
    [47]
    TORRES G, SALLADAY-PEREZ IA, DHINGRA A, et al. Genetic origins, regulators, and biomarkers of cellular senescence[J]. Trends Genet, 2024, 40( 12): 1018- 1031. DOI: 10.1016/j.tig.2024.08.007.
    [48]
    MONCSEK A, AL-SURAIH MS, TRUSSONI CE, et al. Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout(Mdr2-/-) mice[J]. Hepatology, 2018, 67( 1): 247- 259. DOI: 10.1002/hep.29464.
    [49]
    YIN YJ, CHEN HH, WANG YZ, et al. Roles of extracellular vesicles in the aging microenvironment and age-related diseases[J]. J Extracell Vesicles, 2021, 10( 12): e12154. DOI: 10.1002/jev2.12154.
    [50]
    SURAIH MS AL, TRUSSONI CE, SPLINTER PL, et al. Senescent cholangiocytes release extracellular vesicles that alter target cell phenotype via the epidermal growth factor receptor[J]. Liver Int, 2020, 40( 10): 2455- 2468. DOI: 10.1111/liv.14569.
    [51]
    RUDNITSKY E, BRAIMAN A, WOLFSON M, et al. Stem cell-derived extracellular vesicles as senotherapeutics[J]. Ageing Res Rev, 2024, 99: 102391. DOI: 10.1016/j.arr.2024.102391.
    [52]
    CHEN WY, ZHU JQ, LIN FY, et al. Human placenta mesenchymal stem cell-derived exosomes delay H2O2 - induced aging in mouse cholangioids[J]. Stem Cell Res Ther, 2021, 12( 1): 201. DOI: 10.1186/s13287-021-02271-3.
    [53]
    CHEN LX, ZHOU TH, WHITE T, et al. The apelin-apelin receptor axis triggers cholangiocyte proliferation and liver fibrosis during mouse models of cholestasis[J]. Hepatology, 2021, 73( 6): 2411- 2428. DOI: 10.1002/hep.31545.
    [54]
    CECI L, FRANCIS H, ZHOU TH, et al. Knockout of the tachykinin receptor 1 in the Mdr2-/-(Abcb4-/-) mouse model of primary sclerosing cholangitis reduces biliary damage and liver fibrosis[J]. Am J Pathol, 2020, 190( 11): 2251- 2266. DOI: 10.1016/j.ajpath.2020.07.007.
    [55]
    GLASER S, GAUDIO E, RENZI A, et al. Knockout of the neurokinin-1 receptor reduces cholangiocyte proliferation in bile duct-ligated mice[J]. Am J Physiol Gastrointest Liver Physiol, 2011, 301( 2): G297- G305. DOI: 10.1152/ajpgi.00418.2010.
    [56]
    WAN Y, CECI L, WU N, et al. Knockout of α-calcitonin gene-related peptide attenuates cholestatic liver injury by differentially regulating cellular senescence of hepatic stellate cells and cholangiocytes[J]. Lab Invest, 2019, 99( 6): 764- 776. DOI: 10.1038/s41374-018-0178-5.
    [57]
    SCHUMACHER JD, GUO GL. Regulation of hepatic stellate cells and fibrogenesis by fibroblast growth factors[J]. Biomed Res Int, 2016, 2016: 8323747. DOI: 10.1155/2016/8323747.
    [58]
    WU G, YU F, XIAO Z, et al. Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro[J]. Br J Cancer, 2011, 105( 1): 146- 153. DOI: 10.1038/bjc.2011.190.
    [59]
    O’BRIEN A, ZHOU TH, WHITE T, et al. FGF1 signaling modulates biliary injury and liver fibrosis in the Mdr2-/- mouse model of primary sclerosing cholangitis[J]. Hepatol Commun, 2022, 6( 7): 1574- 1588. DOI: 10.1002/hep4.1909.
    [60]
    SASAKI M, SATO Y, NAKANUMA Y. Interferon-induced protein with tetratricopeptide repeats 3 may be a key factor in primary biliary cholangitis[J]. Sci Rep, 2021, 11( 1): 11413. DOI: 10.1038/s41598-021-91016-6.
    [61]
    ZHANG WT, LI YL, XIN SY, et al. The emerging roles of IFIT3 in antiviral innate immunity and cellular biology[J]. J Med Virol, 2023, 95( 1): e28259. DOI: 10.1002/jmv.28259.
    [62]
    DONG ZN, LUO YH, YUAN ZC, et al. Cellular senescence and SASP in tumor progression and therapeutic opportunities[J]. Mol Cancer, 2024, 23( 1): 181. DOI: 10.1186/s12943-024-02096-7.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (329) PDF downloads(27) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return